Sarepta Announces Positive Topline Three-Year Embark Results Showing Elevidys Significantly Slows Disease Progression On Key Functional Measures In Ambulatory Duchenne Patients

At a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after treatment (n=52) ELEVIDYS gene therapy demonstrated 70% or greater reduction in the rate of decline ...Read more